Targovax ASA issues options to employees
Primary insiders in Targovax ASA have received the following options grants, according to the terms described above:
Chief Executive Officer Øystein Soug has been granted 150,000 share options. Following the grant, he holds 200,000 shares and 1,310,000 options in the Company.
Chief Medical Officer Magnus Jäderberg has been granted 90,000 share options. Following the grant, he holds 20,000 shares and 930,000 options in the Company.
VP Regulatory Affairs Ingunn Munch Lindvig has been granted 90,000 share options. Following the grant, she holds 10,000 shares and 117,000 options in the Company.
Chief Business Officer Erik Digman Wiklund has been granted 130,000 share options. Following the grant, he holds no shares and 560,000 options in the Company.
Chief Financial Officer Torbjørn Furuseth has been granted 130,000 share options. Following the grant, he holds 15,000 shares and 430,000 options in the Company.
Director, QC, Viral Products Kristiina Hyvärinen has been granted 90,000 share options. Following the grant, she holds no shares and 175,500 options in the Company.
Head of Clinical Science Anne-Sophie Wiborg Møller has been granted 90,000 share options. Following the grant, she holds no shares and 170,500 options in the Company.
###
For further information please contact:
Øystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com